Lumida
/ZBH
⌘K
Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings Inc

ZBH
$93.49USD+1.14%+1.05 today

MARKET CAP

17.8B

P/E (TTM)

24.2x

FWD P/E

DAY RANGE

$92 – $94

52W RANGE

$79
$107

AI Summary

Stalk
Sell NowMedium

Price has formed a Bearish Pivot Point beneath converged 9-, 20-, and 50-day EMAs, signaling structural downside repair. The recent bounce off the 200-day SMA remains relief only, with no reclaim of key moving averages. Medium-term bias is bearish, and short-term conditions favor selling into rallies toward the 95.3–96.0 resistance band. Long-term uptrend persists above the 200-day SMA, but only sustained acceptance above the short-term EMAs and 50-day SMA would reverse this stance.

  • High earnings yield indicates potential value opportunity.
  • Q2 2026 revenue est. $2.14B, up 2.9% YoY.
  • Negative profitability factors signal margin inefficiencies.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$6.8B$6.9B$7.4B$7.7B$8.2B
YoY %+11.4%+1.6%+6.5%+3.8%+7.2%
P / Sales3.9x3.9x3.4x2.8x2.2x
EV / Sales5.4x5.1x4.6x3.9x3.4x
Gross Profit, Adj.$4.9B$4.9B$5.3B$5.5B$5.7B
YoY %+13.1%+1.1%+7.9%+3.3%+4.6%
Margin %71.3%70.9%71.8%71.5%69.7%
EV / Gross Profit7.6x7.2x6.4x5.4x4.8x
EBITDA, Adj.$1.9B$2.1B$2.4B$2.5B$2.4B
YoY %+21.2%+9.0%+12.4%+5.0%-5.1%
Margin %28.5%30.5%32.2%32.6%28.8%
EV / EBITDA19.1x16.7x14.3x12.0x11.7x
EBIT$860.3M$696.3M$1.3B$1.3B$1.1B
YoY %+810.4%-19.1%+83.5%+0.6%-14.6%
Margin %12.6%10.0%17.3%16.7%13.3%
EV / EBIT43.2x50.9x26.6x23.3x25.2x
Net Income$401.6M$231.4M$1.0B$903.8M$705.1M
YoY %+389.1%-42.4%+342.5%-11.7%-22.0%
Net Margin5.9%3.3%13.8%11.8%8.6%
EPS (GAAP)$1.91$1.10$4.88$4.43$3.55
YoY %+385.1%-42.4%+343.6%-9.2%-19.9%